Ningjing Lin

2.5k total citations
66 papers, 1.4k citations indexed

About

Ningjing Lin is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Ningjing Lin has authored 66 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pathology and Forensic Medicine, 37 papers in Oncology and 15 papers in Immunology. Recurrent topics in Ningjing Lin's work include Lymphoma Diagnosis and Treatment (46 papers), Viral-associated cancers and disorders (20 papers) and CNS Lymphoma Diagnosis and Treatment (11 papers). Ningjing Lin is often cited by papers focused on Lymphoma Diagnosis and Treatment (46 papers), Viral-associated cancers and disorders (20 papers) and CNS Lymphoma Diagnosis and Treatment (11 papers). Ningjing Lin collaborates with scholars based in China, Ethiopia and United States. Ningjing Lin's co-authors include Chunhui Di, Darell D. Bigner, Okezie Obasi Kanu, Ankit I. Mehta, Cory Adamson, Austin K. Mattox, Wen Zheng, Xiaopei Wang, Yan Xie and Jun Zhu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ningjing Lin

62 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ningjing Lin China 15 609 457 407 362 285 66 1.4k
Yeonhee Kim United States 20 402 0.7× 439 1.0× 448 1.1× 423 1.2× 201 0.7× 83 1.5k
Erwin R. Boghaert United States 26 1.0k 1.7× 1.2k 2.6× 321 0.8× 302 0.8× 245 0.9× 58 2.5k
Shao Ning Yang United States 17 514 0.8× 816 1.8× 380 0.9× 213 0.6× 451 1.6× 26 1.5k
Yuanxuan Xia United States 12 402 0.7× 436 1.0× 118 0.3× 515 1.4× 492 1.7× 43 1.4k
Yongfeng Xu China 21 488 0.8× 572 1.3× 116 0.3× 169 0.5× 430 1.5× 72 1.7k
Becker Hewes United States 18 1000 1.6× 617 1.4× 388 1.0× 457 1.3× 624 2.2× 34 2.0k
Jayant Sastri Goda India 21 438 0.7× 323 0.7× 335 0.8× 318 0.9× 75 0.3× 90 1.4k
Élodie Vauléon France 24 596 1.0× 522 1.1× 151 0.4× 449 1.2× 302 1.1× 60 1.8k
Andrew J. Tsung United States 25 352 0.6× 706 1.5× 127 0.3× 366 1.0× 284 1.0× 54 1.5k
Hee Jin Cho South Korea 21 421 0.7× 513 1.1× 105 0.3× 302 0.8× 256 0.9× 67 1.5k

Countries citing papers authored by Ningjing Lin

Since Specialization
Citations

This map shows the geographic impact of Ningjing Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ningjing Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ningjing Lin more than expected).

Fields of papers citing papers by Ningjing Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ningjing Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ningjing Lin. The network helps show where Ningjing Lin may publish in the future.

Co-authorship network of co-authors of Ningjing Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Ningjing Lin. A scholar is included among the top collaborators of Ningjing Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ningjing Lin. Ningjing Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yanfei, Lingyan Ping, Yuqin Song, et al.. (2024). Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial. BMC Medicine. 22(1). 107–107. 2 indexed citations
2.
Liu, Yanyan, Ningjing Lin, Zhihua Yao, et al.. (2024). Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 42(16_suppl). e19040–e19040. 1 indexed citations
3.
Song, Yuqin, Ningjing Lin, Xingguo Liu, et al.. (2024). Preclinical and First-in-Human Phase I Study of Bruton Tyrosine Kinase Degrader HZ-Q1070 in Patients with Recurrent or Refractory B-Cell Malignancies. Blood. 144(Supplement 1). 6286–6286. 2 indexed citations
4.
Sun, Yan, Yan Xie, Ningjing Lin, et al.. (2024). Immunotyping of peripheral blood lymphocytes by flow cytometry reveals Th cell as a potential prognostic biomarker for extranodal NK/T-cell lymphoma. Annals of Hematology. 103(5). 1643–1653. 2 indexed citations
5.
Yang, Jianjun, Yan Zhang, Tao Luo, et al.. (2023). Sequential Ubiquitination and Phosphorylation Epigenetics Reshaping by MG132‐Loaded Fe‐MOF Disarms Treatment Resistance to Repulse Metastatic Colorectal Cancer. Advanced Science. 10(23). e2301638–e2301638. 32 indexed citations
6.
Liu, Weiping, Ningjing Lin, Yan Xie, et al.. (2023). Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Signal Transduction and Targeted Therapy. 8(1). 356–356.
7.
8.
Ying, Zhitao, Ting He, Shanzhao Jin, et al.. (2022). A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. Chinese Journal of Cancer Research. 34(1). 53–62. 5 indexed citations
9.
10.
Lin, Ningjing, Yuqin Song, & Jun Zhu. (2020). Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives. Chinese Journal of Cancer Research. 32(3). 303–318. 27 indexed citations
11.
12.
Liu, Yalu, Lijuan Deng, Lingyan Ping, et al.. (2019). ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma. Cancer Cell International. 19(1). 32–32. 23 indexed citations
13.
Gao, Bixia, Ningjing Lin, Suxia Wang, & Yu Wang. (2018). Minimal change disease associated with anti-PD1 immunotherapy: a case report. BMC Nephrology. 19(1). 156–156. 24 indexed citations
14.
Wang, Xiaopei, Yan Xie, Weiping Liu, et al.. (2018). Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas. International Journal of Medical Sciences. 15(9). 867–874. 11 indexed citations
15.
Zheng, Wen, Yuhuan Gao, Xiaoyan Ke, et al.. (2018). PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. BMC Cancer. 18(1). 910–910. 8 indexed citations
16.
Ying, Zhitao, Lan Mi, Xuejuan Wang, et al.. (2017). Prognostic value of pre- and post-transplantation 18F-fluorodeoxyglucose positron emission tomography results in non-Hodgkin lymphoma patients receiving autologous stem cell transplantation. Chinese Journal of Cancer Research. 29(6). 561–571. 3 indexed citations
17.
Jia, Jing, Yuqin Song, Ningjing Lin, et al.. (2016). Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome. Annals of Hematology. 95(12). 2023–2031. 29 indexed citations
18.
Xie, Yan, Yuntao Zhang, Wen Zheng, et al.. (2015). Outcomes of dose-adjusted Berlin–Frankfurt–Münster-90 regimen without radiotherapy in adolescents and adults with T cell lymphoblastic lymphoma. Medical Oncology. 32(4). 110–110. 6 indexed citations
19.
Ping, Lingyan, Ning Ding, Yunfei Shi, et al.. (2014). [Clinical characteristics and prognosis analysis of patients with LMP-1 positive Hodgkin's lymphoma after EBV infection].. PubMed. 22(1). 78–84. 4 indexed citations
20.
Lin, Ningjing, Chunhui Di, Jinrong Fu, et al.. (2012). Deletion or Epigenetic Silencing of AJAP1 on 1p36 in Glioblastoma. Molecular Cancer Research. 10(2). 208–217. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yeonhee Kim Breakdown of academic impact, for papers by Erwin R. Boghaert Breakdown of academic impact, for papers by Shao Ning Yang Breakdown of academic impact, for papers by Yuanxuan Xia Breakdown of academic impact, for papers by Yongfeng Xu Breakdown of academic impact, for papers by Becker Hewes Breakdown of academic impact, for papers by Jayant Sastri Goda Breakdown of academic impact, for papers by Élodie Vauléon Breakdown of academic impact, for papers by Andrew J. Tsung Breakdown of academic impact, for papers by Hee Jin Cho
Rankless by CCL
2026